A: MT-2 (Melanotan II) is a cyclic heptapeptide (7 amino acids, MW 1,024.18 g/mol) that activates four melanocortin receptor subtypes: MC1R, MC3R, MC4R, and MC5R
Potential Benefits: The combination is suggested to potentially enhance fat reduction (especially abdominal fat), improve muscle mass and recovery, and potentially minimize the side effects associated with conventional GH therapy
MET forms clusters at excitatory synapses in relatively mature cultured hippocampal neurons and co-localizes with the post-synaptic protein PSD-95 and with the glutamatergic N-methyl-D-aspartate (NMDA) receptor subunit GluN2B (Tyndall and Walikonis, 2006)
Symptoms of G6PD deficiency are triggered by exposure to certain foods, medications, infection and/or environmental factors 2,4
Nevertheless, the annual distribution of adverse event reports revealed that tirzepatide exceeded semaglutide in 2023 and early 2024, consistent with its rising clinical use [107]